Ultragenyx is trading 5.45% lower at $14.39, with no new company announcement clearly tied to the October 5 intraday decline.
- The Phase 3 Aspire study in Angelman syndrome missed its primary and key secondary endpoints.
- Ultragenyx said it would evaluate the program and consider significant expense reductions. This news preceded the current session and is background, not a confirmed trigger for today’s move.